On September 10, Oklo Inc. fell 5.19% in regular trading, trading at approximately $40.42 per share, with turnover of $203 million. The decline came amid intensifying insider selling activity that raised concerns over management confidence.

On the news front, CEO and 10% shareholder Jacob DeWitte and COO Caroline Cochran had each filed Form 144 to sell up to 400,000 shares of Class A common stock, with a combined market value of approximately $31 million. Recent disclosures showed DeWitte sold over 120,000 shares and Cochran sold 40,000 shares in a single day in early September, amplifying bearish sentiment. Additionally, a related leveraged ETF was halted on the same day due to undisclosed information, further exacerbating short-term selling pressure.

Despite the near-term headwinds, analyst coverage remains constructive. Piper Sandler recently initiated coverage with an Overweight rating, and the consensus mean price target stands at $75.03, well above the current trading level. On the fundamental side, the company achieved a key milestone in July when its Groves Isotope Test Reactor received DOE safety approval, advancing toward first criticality.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)